Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells.
ABCB5
GD2
HER2
TRP2
gp100
melanoma
p53
target
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
24 Mar 2021
24 Mar 2021
Historique:
received:
05
03
2021
revised:
15
03
2021
accepted:
18
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma. Expression of melanoma-specific antigen recognized by the respective CAR or TCR directly or presented by HLA molecules is an indispensable prerequisite for this innovative therapy. In this study, we investigated in 168 FFPE tumor specimens of patients with stage I-IV melanoma the protein expression of HER2, TRP2, ABCB5, gp100, p53, and GD2 by immunohistochemistry (IHC). These results were correlated with clinical parameters. Membrane expression of HER2 and GD2 was also investigated in ten melanoma cell lines by flow cytometry for which corresponding tumors were analyzed by IHC. Our results demonstrated that gp100 was the most frequently overexpressed protein (61%), followed by TRP2 (50%), GD2 (38%), p53 (37%), ABCB5 (17%), and HER2 (3%). TRP2 expression was higher in primary tumors compared to metastases (
Identifiants
pubmed: 33805080
pii: life11040269
doi: 10.3390/life11040269
pmc: PMC8064084
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutschen Konsortium für Translationale Krebsforschung
ID : UniCAR NK cells
Références
J Carcinog. 2003 Nov 16;2(1):8
pubmed: 14617373
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10698-703
pubmed: 11526213
J Cell Biol. 2001 Feb 19;152(4):809-24
pubmed: 11266471
Front Oncol. 2020 Oct 28;10:593383
pubmed: 33194757
Ann Oncol. 2012 Sep;23 Suppl 8:viii10-4
pubmed: 22918922
Clin Cancer Res. 2009 Sep 15;15(18):5852-60
pubmed: 19737958
Expert Opin Ther Targets. 2015 Mar;19(3):349-62
pubmed: 25604432
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344957
Int J Cancer. 2000 Apr 15;86(2):269-75
pubmed: 10738256
J Clin Invest. 2019 Mar 1;129(3):1109-1114
pubmed: 30714987
J Clin Oncol. 1987 Sep;5(9):1430-40
pubmed: 3625258
J Immunol. 2002 Nov 15;169(10):6036-47
pubmed: 12421991
Cancer Res. 2000 Jan 15;60(2):253-8
pubmed: 10667570
Transl Res. 2017 Sep;187:1-10
pubmed: 28502785
Melanoma Res. 2004 Jun;14(3):207-10
pubmed: 15179190
Sci Rep. 2020 Feb 7;10(1):2141
pubmed: 32034289
J Immunother. 2009 Feb-Mar;32(2):129-39
pubmed: 19238011
Breast Cancer Res Treat. 2003 Dec;82(3):155-64
pubmed: 14703062
Cancer Res. 2005 May 15;65(10):4320-33
pubmed: 15899824
Cancer Res. 2019 Mar 1;79(5):899-904
pubmed: 30622115
Annu Rev Biochem. 2016 Jun 2;85:375-404
pubmed: 27145840
Clin Cancer Res. 2020 Nov 15;26(22):5869-5878
pubmed: 32816891
Int J Cancer. 2005 Oct 10;116(6):944-8
pubmed: 15856458
Cancer Immunol Res. 2019 Apr;7(4):534-543
pubmed: 30709841
J Invest Dermatol. 1996 Jul;107(1):63-7
pubmed: 8752841
Clin Cancer Res. 2000 Mar;6(3):979-86
pubmed: 10741724
Scand J Immunol. 2000 Feb;51(2):128-33
pubmed: 10652158
Br J Cancer. 2001 Apr 20;84(8):1052-7
pubmed: 11308253
J Exp Med. 1993 Aug 1;178(2):489-95
pubmed: 8340755
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Cells. 2013 Dec 06;2(4):751-67
pubmed: 24709879
Blood. 2011 Dec 1;118(23):6050-6
pubmed: 21984804
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Am J Surg Pathol. 1998 May;22(5):595-602
pubmed: 9591730
Melanoma Res. 2008 Feb;18(1):47-55
pubmed: 18227708
J Exp Med. 1994 Mar 1;179(3):1005-9
pubmed: 8113668
Adv Exp Med Biol. 2008;624:265-82
pubmed: 18348463
Cancer Res. 2000 Dec 15;60(24):6995-7001
pubmed: 11156402
Int J Cancer. 2000 Aug 1;87(3):399-404
pubmed: 10897046
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
J Hematol Oncol. 2018 Jan 03;11(1):1
pubmed: 29298689
Nat Rev Clin Oncol. 2018 Jan;15(1):13-30
pubmed: 28948977
J Exp Med. 1997 Feb 3;185(3):453-9
pubmed: 9053445
Cancers (Basel). 2019 May 20;11(5):
pubmed: 31137488
Cancer Res. 1998 Nov 1;58(21):4895-901
pubmed: 9809996